Skip to main content

Table 2 Overview of various inorganic nanocarriers for delivery of anticancer therapeutics

From: Current trends and challenges in cancer management and therapy using designer nanomaterials

Nanocarrier

Materials

Drug

Target

Refs.

Metal nanoparticle

Pluronic-b-poly(l-lysine) and gold nanoparticles

Paclitaxel

Human breast cancer (in vitro/in vivo)

[160]

Folic acid, transferrin and gold nanoparticles

Gemcitabine

Human mammary gland breast adenocarcinoma (in vitro)

[161]

Apatite stacked gold nanoparticles

Docetaxel

Human liver cancer (in vitro)

[140]

Chitosan and gold nanoparticles

Doxorubicin

Human breast cancer (in vitro)

[142]

CTAB and gold nanoparticles

Fluorouracil

Human skin cancer (in vitro/in vivo)

 

Polyethylenimine and silver nanoparticles

Paclitaxel

Human liver carcinoma (in vitro)

[162]

Silver nanoparticles

Imatinib

Human breast adenocarcinoma (in vitro)

[163]

PEG and silver nanoparticles

Methotrexate

Human breast cancer (in vitro)

[164]

Metal oxide nanoparticle

PEG and gadolinium oxide nanoparticles

Doxorubicin

Human lung carcinoma, human pancreas ductal adenocarcinoma, human glioblastoma (in vitro)

[165]

Folic acid, PEG and superparamagnetic iron oxide nanoparticles

Doxorubicin

Human breast cancer (in vitro/in vivo)

[166]

BSA, folic acid and nickel oxide nanoparticles

Doxorubicin

Human cervical epithelial malignant carcinoma (in vitro)

[167]

PEG and superparamagnetic iron oxide nanoparticles

Doxorubicin

Human colorectal adenocarcinoma (in vitro/in vivo)

[168]

Zinc oxide nanoparticles

Doxorubicin

Human breast cancer, human colorectal adenocarcinoma (in vitro/in vivo)

[169]

Superparamagnetic iron oxide nanoparticles

Docetaxel

Human prostate carcinoma (in vitro)

[170]

PEG, dextran, superparamagnetic iron oxide nanoparticles

Cetuximab

Human squamous carcinoma

[171]

Carbon nanomaterial

PEG and single-walled carbon nanotubes

Cisplatin

Head and neck cancer (in vitro/in vivo)

[172]

PEG, anionic polymer, dimethylmaleic acid and carbon dots

Cisplatin IV

Human ovarian carcinoma (in vitro/in vivo)

[173]

Chitosan, single walled carbon nanotubes

Doxorubicin

Human cervical epithelial malignant carcinoma (in vitro)

[174]

Endoglin, iron, single-walled carbon nanotubes

Doxorubicin

Murine breast cancer (in vitro/in vivo)

[175]

Carbon nanoparticles

Methotrexate

Human lung carcinoma (in vitro)

[176]

Human serum albumin, single-walled carbon nanotubes

Paclitaxel

Human breast cancer (in vitro)

[177]

Carboxymethyl chitosan, fluorescein isothiocyanate, lactobionic acid, and graphene oxides

Doxorubicin

Human hepatocarcinoma (in vitro)

[178]

PEG, nanographene oxides

Resveratrol

Mouse mammary carcinoma (in vitro/in vivo)

[179]

Dendrimer, gadolinium diethylene triamine pentaacetate, prostate stem cell antigen monoclonal antibody, graphene oxides

Doxorubicin

Prostate cancer (in vivo)

[180]

Mesoporous silica nanoparticle

PEG, amino-β-cyclodextrin, folic acid, mesoporous silica nanoparticles

Doxorubicin

Breast cancer (in vivo)

[181]

Lanthanide doped upconverting nanoparticle, mesoporous silica nanoparticles

Doxorubicin

Murine hepatocellular carcinoma (in vitro/in vivo)

[73]

Bismuth(III) sulphide nanoparticles, mesoporous silica nanoparticles

Doxorubicin

Multidrug-resistant breast cancer (in vitro/in vivo)

[182]

(S)-2-(4-isothiocyanatobenzyl)-1,4,7-triazacyclononane-1,4,7-triaceticacid, PEG, Hollow mesoporous silica nanoparticles

Sunitinib

Human glioblastoma (in vitro/in vivo)

[183]

Poly(2-(diethylamino)ethyl methacrylate), Hollow mesoporous silica nanoparticles

Doxorubicin

Human cervical epithelial malignant carcinoma (in vitro)

[184]

Folic acid, dexamethasone, mesoporous silica nanoparticles

Doxorubicin

Human cervical epithelial malignant carcinoma (in vitro)

[185]

Glucose, poly(ethylene imine), mesoporous silica nanoparticles

Celastrol

Human cervical epithelial malignant carcinoma, human lung carcinoma (in vitro)

[186]

Aptamer, mesoporous silica nanoparticles

Doxorubicin

Colon cancer (in vitro)

[187]

  1. The table illustrates the type of inorganic nanomaterial used as nanocarrier, the drug loaded on the carrier and target site